Jul 17, 2020 · We describe the development and in vitro characterization of C1qNb75, a single domain antibody (nanobody) specific for C1q, the pattern recognition molecule of the classical …

We target C1q to block all damaging components of the immune system’s classical complement pathway. Our next generation of early complement inhibitors targets diseases of the body, …

Here we report an evaluation of the safety, tolerability, and ocular pharmacokinetics (PK) and pharmacodynamics of intravitreal (IVT) injections of ANX007, an anti-C1q monoclonal …

Sep 20, 2022 · Microglia and complement can mediate neurodegeneration in Alzheimer’s disease (AD). By integrative multi-omics analysis, here we show that astrocytic and microglial proteins …

Overall, C1qNb75 represents a high-affinity nanobody-based inhibitor of IgG- and IgM-mediated activation of the classical pathway and may serve as a valuable reagent in mechanistic and …

ANX005 is a humanized immunoglobulin G4 recombinant antibody against C1q that inhibits its function as the initiating molecule of the classical complement cascade.

Interestingly, most recently Elkon and colleagues, using an inhibitor of C1s, demonstrated that C1q facilitates apoptotic cell engulfment independent of classical pathway activation (Colonna …

May 13, 2022 · This review describes the fundamental roles of C1q in various microenvironments and focuses on the importance of the interactions of C1q and its receptors with the inhibitory …

This report provides evidence that a 30 kDa core protein component of the proteoglycan macromolecule contains most of the C1q inhibitory activity. This inhibitory activity occurs as a …

Oct 12, 2016 · We demonstrate that C1q in itself is a potent inhibitor of allergic asthma and further, that it acts directly via plasmacytoid DCs (pDCs), in the absence of any expansion of …